Drugs / Danosumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05797259 | Mar 2019 → Mar 2023 | neurogenic arthropathy | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Danosumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05797259 ↗ |
| Route | Subcutaneous | “60 mg subcutaneous Danosumab” NCT05797259 ↗ |